 Credit Suisse analyst Jailendra Singh upgraded his rating on Teladocs stock from neutral to outperform and boosted his price forecast from 225 to 249. Singhs new target price represents potential gains of roughly 25 for investors, based on Teladocs current price near 200. Credit Suisse analyst Jailendra Singh says a merger between Teladoc and Livongo will create a powerful force in digital health. 